Three questions. One, how fungible are cash flows between Hindalco and Novelis, I mean, from a tax leakage standpoint and various FEMA regulation standpoint?
Basically, I was coming from the point of view that given that these are two standalone businesses, but when you try to look at a console net debt to EBITDA of less than 2, it is essentially inferring that the fungibility is extremely strong. So I just wanted to verify if that's really the case?
Three questions all on PI Health Sciences. One, of the 700 R&D staff or 700 scientists that you have in your roles, how much would be dedicated to PI Health Sciences and how many to PI Industries? Second, in the current nature of the PI Health Science business, is it more indexed to generic APIs or generic intermediates, if you could just give us a pulse of what the current structure of the business is and how do you intend to transform this business over the next 2 years or 3 years as you achieve the $200-$250 million run rate? And number three, what are the internal milestones that you have, if you could just give us some sense qualitatively to calibrate the traction in this business and considering that it has been about 14-15 months, how have you progressed in terms of reaching those milestones that you had set out initially and what are the milestones going forward? So, three questions from me?
Sir, just a follow up, is this business index ed to cater to big pharma or is it index ed to cater to the requirements of EBPs? And second, are you looking at focusing on specific therapeutic areas or specific technology platforms, just to follow up?
Sir, typically for your Spec Chem . business specifically, what is your working capital days between debtors and finished good stock?
Okay. And, have you seen an expansion here versus, say, two years back?
Hi, ma’am. Good afternoon. A couple of questions from my side. Specifically on the subsidy. I could gather that there has been a sharp reduction in the NBS rate and while in the first half the reduction was not as significant as the reduction in the global commodity prices that I think seems to have been made up in the current sub sidy. While you have been prudent in terms of providing for it, but purely on a per ton margin basis, how do yo u see H2 period versus what we have seen in H1 and the previous year as well?
That is helpful. The second question, when we came into FY2024, we were anticipating about anywhere between 6 % to 10% volume growth in the Phosphatics business. So far in H1, things have been largely flat on the manufacturing side. So how are you lo oking at H2, and the third one, if you could give us a split of the 580 Crores Capex in H1 FY2024? Thank you.
Good evening, couple of questions from my side one on the flooring and the second one on the domestic B2C textile business, so on the flooring business your unit realization seem ed to have fallen substantially what is driving this, is it a consci ous effort to gain market share, utilize the benefits of additional operating leverage so that is one and the second one on the domestic B2C business I am not sure but did I hear it correctly is this business b urning any cash on a quarterly basis that is number one and number two how are you managing the supply chain to sell your MBOs?
Madam if I may you spoke about distributors what is the number of distributors right now which are helping MBOs?
Hi, good afternoon. Three questions from my side. One because of the IRA right, there is an implication that perhaps it woul d result in transitioning of in vestments from out of small molecule developments towards large molecule developments becau se of the stipulations laid out in the IRA. Are you seeing any signs of that happening in your interaction with the customers so that is one? Second in terms of your large molecul e outsourcing business, are there any developments that you are seeing other than Zoetis co ntract and third given that we have already received the approval for the Mangalore API fac ility, if you could comment on the ramp up of that business, say in FY2025 and 2026 and last fourth a small bookkeeping one, you said $80 million of capex guidance for FY2 024. I would believe this is organic capex, Stellis acquisition will be over and above if you could clarify on that? Thanks.
Yes, it did.